Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Pozycja w akcjach #25843
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Cena akcji
$0.40861751
Kapitalizacja rynkowa
$45.81M
Zmiana (1 dzień)
-1.15%
Zmiana (1 rok)
-46.41%
Kraj
TW
Handel TaiRx, Inc. (6580)

Kategoria

Wskaźnik P/B dla TaiRx, Inc. (6580)
Wskaźnik P/B na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji TaiRx, Inc., obecny wskaźnik P/B (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/B dla TaiRx, Inc. od 2026 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
Za mało danych dla podanych dat.
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US